 | • レポートコード：MRC23Q36308 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の四肢麻痺治療市場について調査・分析し、世界の四肢麻痺治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（経口、点滴、その他）、用途別セグメント分析（病院薬局、小売店、ドラッグストア、オンラインストア）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Merck、Sanofi Pharmaceuticals、Baxter International、Zydus Cadila、GlaxoSmithKline、AstraZeneca、Cipla、Johnson & Johnson、Bristol Myers Squibb、Eli Lily、Teva Pharmaceuticals、Takeda Pharmaceutical、Hoffmann La Roche、Sun Pharmaceuticalsなどが含まれています。 世界の四肢麻痺治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、四肢麻痺治療市場規模を推定する際に考慮しました。本レポートは、四肢麻痺治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、四肢麻痺治療に関するビジネス上の意思決定に役立てることを目的としています。 ・四肢麻痺治療市場の概要 - 四肢麻痺治療のタイプ別セグメント - 世界の四肢麻痺治療市場規模：タイプ別分析（経口、点滴、その他） - 四肢麻痺治療の用途別セグメント - 世界の四肢麻痺治療市場規模：用途別分析（病院薬局、小売店、ドラッグストア、オンラインストア） - 世界の四肢麻痺治療市場規模予測（2018年-2029年） ・四肢麻痺治療市場の成長トレンド - 四肢麻痺治療の地域別市場規模（2018年-2029年） - 四肢麻痺治療市場ダイナミクス - 四肢麻痺治療の業界動向 - 四肢麻痺治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：経口、点滴、その他 - 世界の四肢麻痺治療のタイプ別市場規模（2018年-2023年） - 世界の四肢麻痺治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院薬局、小売店、ドラッグストア、オンラインストア - 世界の四肢麻痺治療の用途別市場規模（2018年-2023年） - 世界の四肢麻痺治療の用途別市場規模（2024年-2029年） ・四肢麻痺治療の地域別市場規模 - 北米の四肢麻痺治療市場規模（2018年-2029年） - アメリカの四肢麻痺治療市場規模（2018年-2029年） - ヨーロッパの四肢麻痺治療市場規模（2018年-2029年） - アジア太平洋の四肢麻痺治療市場規模（2018年-2029年） - 中国の四肢麻痺治療市場規模（2018年-2029年） - 日本の四肢麻痺治療市場規模（2018年-2029年） - 韓国の四肢麻痺治療市場規模（2018年-2029年） - インドの四肢麻痺治療市場規模（2018年-2029年） - オーストラリアの四肢麻痺治療市場規模（2018年-2029年） - 中南米の四肢麻痺治療市場規模（2018年-2029年） - 中東・アフリカの四肢麻痺治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Merck、Sanofi Pharmaceuticals、Baxter International、Zydus Cadila、GlaxoSmithKline、AstraZeneca、Cipla、Johnson & Johnson、Bristol Myers Squibb、Eli Lily、Teva Pharmaceuticals、Takeda Pharmaceutical、Hoffmann La Roche、Sun Pharmaceuticals ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Quadriplegia Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Quadriplegia Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Quadriplegia Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Quadriplegia Treatment in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Quadriplegia Treatment include Merck, Sanofi Pharmaceuticals, Baxter International, Zydus Cadila, GlaxoSmithKline, AstraZeneca, Cipla, Johnson & Johnson and Bristol Myers Squibb, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Quadriplegia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Quadriplegia Treatment.
The Quadriplegia Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Quadriplegia Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Quadriplegia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Merck
Sanofi Pharmaceuticals
Baxter International
Zydus Cadila
GlaxoSmithKline
AstraZeneca
Cipla
Johnson & Johnson
Bristol Myers Squibb
Eli Lily
Teva Pharmaceuticals
Takeda Pharmaceutical
Hoffmann La Roche
Sun Pharmaceuticals
Segment by Type
Oral
Intravenous
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Quadriplegia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Quadriplegia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral
1.2.3 Intravenous
1.2.4 Others
1.3 Market by Application
1.3.1 Global Quadriplegia Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Drug Stores
1.3.5 Online Stores
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Quadriplegia Treatment Market Perspective (2018-2029)
2.2 Quadriplegia Treatment Growth Trends by Region
2.2.1 Global Quadriplegia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Quadriplegia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Quadriplegia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Quadriplegia Treatment Market Dynamics
2.3.1 Quadriplegia Treatment Industry Trends
2.3.2 Quadriplegia Treatment Market Drivers
2.3.3 Quadriplegia Treatment Market Challenges
2.3.4 Quadriplegia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Quadriplegia Treatment Players by Revenue
3.1.1 Global Top Quadriplegia Treatment Players by Revenue (2018-2023)
3.1.2 Global Quadriplegia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Quadriplegia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Quadriplegia Treatment Revenue
3.4 Global Quadriplegia Treatment Market Concentration Ratio
3.4.1 Global Quadriplegia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Quadriplegia Treatment Revenue in 2022
3.5 Quadriplegia Treatment Key Players Head office and Area Served
3.6 Key Players Quadriplegia Treatment Product Solution and Service
3.7 Date of Enter into Quadriplegia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Quadriplegia Treatment Breakdown Data by Type
4.1 Global Quadriplegia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Quadriplegia Treatment Forecasted Market Size by Type (2024-2029)
5 Quadriplegia Treatment Breakdown Data by Application
5.1 Global Quadriplegia Treatment Historic Market Size by Application (2018-2023)
5.2 Global Quadriplegia Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Quadriplegia Treatment Market Size (2018-2029)
6.2 North America Quadriplegia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Quadriplegia Treatment Market Size by Country (2018-2023)
6.4 North America Quadriplegia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Quadriplegia Treatment Market Size (2018-2029)
7.2 Europe Quadriplegia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Quadriplegia Treatment Market Size by Country (2018-2023)
7.4 Europe Quadriplegia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Quadriplegia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Quadriplegia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Quadriplegia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Quadriplegia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Quadriplegia Treatment Market Size (2018-2029)
9.2 Latin America Quadriplegia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Quadriplegia Treatment Market Size by Country (2018-2023)
9.4 Latin America Quadriplegia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Quadriplegia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Quadriplegia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Quadriplegia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Quadriplegia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Quadriplegia Treatment Introduction
11.1.4 Merck Revenue in Quadriplegia Treatment Business (2018-2023)
11.1.5 Merck Recent Development
11.2 Sanofi Pharmaceuticals
11.2.1 Sanofi Pharmaceuticals Company Detail
11.2.2 Sanofi Pharmaceuticals Business Overview
11.2.3 Sanofi Pharmaceuticals Quadriplegia Treatment Introduction
11.2.4 Sanofi Pharmaceuticals Revenue in Quadriplegia Treatment Business (2018-2023)
11.2.5 Sanofi Pharmaceuticals Recent Development
11.3 Baxter International
11.3.1 Baxter International Company Detail
11.3.2 Baxter International Business Overview
11.3.3 Baxter International Quadriplegia Treatment Introduction
11.3.4 Baxter International Revenue in Quadriplegia Treatment Business (2018-2023)
11.3.5 Baxter International Recent Development
11.4 Zydus Cadila
11.4.1 Zydus Cadila Company Detail
11.4.2 Zydus Cadila Business Overview
11.4.3 Zydus Cadila Quadriplegia Treatment Introduction
11.4.4 Zydus Cadila Revenue in Quadriplegia Treatment Business (2018-2023)
11.4.5 Zydus Cadila Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Quadriplegia Treatment Introduction
11.5.4 GlaxoSmithKline Revenue in Quadriplegia Treatment Business (2018-2023)
11.5.5 GlaxoSmithKline Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Quadriplegia Treatment Introduction
11.6.4 AstraZeneca Revenue in Quadriplegia Treatment Business (2018-2023)
11.6.5 AstraZeneca Recent Development
11.7 Cipla
11.7.1 Cipla Company Detail
11.7.2 Cipla Business Overview
11.7.3 Cipla Quadriplegia Treatment Introduction
11.7.4 Cipla Revenue in Quadriplegia Treatment Business (2018-2023)
11.7.5 Cipla Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Detail
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Quadriplegia Treatment Introduction
11.8.4 Johnson & Johnson Revenue in Quadriplegia Treatment Business (2018-2023)
11.8.5 Johnson & Johnson Recent Development
11.9 Bristol Myers Squibb
11.9.1 Bristol Myers Squibb Company Detail
11.9.2 Bristol Myers Squibb Business Overview
11.9.3 Bristol Myers Squibb Quadriplegia Treatment Introduction
11.9.4 Bristol Myers Squibb Revenue in Quadriplegia Treatment Business (2018-2023)
11.9.5 Bristol Myers Squibb Recent Development
11.10 Eli Lily
11.10.1 Eli Lily Company Detail
11.10.2 Eli Lily Business Overview
11.10.3 Eli Lily Quadriplegia Treatment Introduction
11.10.4 Eli Lily Revenue in Quadriplegia Treatment Business (2018-2023)
11.10.5 Eli Lily Recent Development
11.11 Teva Pharmaceuticals
11.11.1 Teva Pharmaceuticals Company Detail
11.11.2 Teva Pharmaceuticals Business Overview
11.11.3 Teva Pharmaceuticals Quadriplegia Treatment Introduction
11.11.4 Teva Pharmaceuticals Revenue in Quadriplegia Treatment Business (2018-2023)
11.11.5 Teva Pharmaceuticals Recent Development
11.12 Takeda Pharmaceutical
11.12.1 Takeda Pharmaceutical Company Detail
11.12.2 Takeda Pharmaceutical Business Overview
11.12.3 Takeda Pharmaceutical Quadriplegia Treatment Introduction
11.12.4 Takeda Pharmaceutical Revenue in Quadriplegia Treatment Business (2018-2023)
11.12.5 Takeda Pharmaceutical Recent Development
11.13 Hoffmann La Roche
11.13.1 Hoffmann La Roche Company Detail
11.13.2 Hoffmann La Roche Business Overview
11.13.3 Hoffmann La Roche Quadriplegia Treatment Introduction
11.13.4 Hoffmann La Roche Revenue in Quadriplegia Treatment Business (2018-2023)
11.13.5 Hoffmann La Roche Recent Development
11.14 Sun Pharmaceuticals
11.14.1 Sun Pharmaceuticals Company Detail
11.14.2 Sun Pharmaceuticals Business Overview
11.14.3 Sun Pharmaceuticals Quadriplegia Treatment Introduction
11.14.4 Sun Pharmaceuticals Revenue in Quadriplegia Treatment Business (2018-2023)
11.14.5 Sun Pharmaceuticals Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details